Coronavirus-Induced Demand Remains Elevated for Fisher & Paykel's Respiratory Products

Fisher & Paykel is well-positioned to benefit from the long-term growth prospects in hospital and home respiratory care. Widespread adoption of what management terms “new applications” in the respiratory care sector is key, and consists of non-invasive ventilation, nasal high-flow therapy and surgical humidification. We see the high-flow devices and consumables, which are marketed under the Optiflow label, as having the most potential reach, as growing clinical evidence is promoting use of this therapy outside of ICU settings in hospital and home environments. The benefits of high-flow oxygen therapy delivered via nasal prongs include better clinical outcomes leading to a shorter length of stay and lower overall treatment cost.